Organogenesis (ORGO) Competitors $4.86 -0.03 (-0.61%) Closing price 04:00 PM EasternExtended Trading$4.93 +0.07 (+1.44%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGO vs. CGON, ALVO, CPRX, TARS, IDYA, OCUL, MLYS, IBRX, DNLI, and IRONShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include CG Oncology (CGON), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), Denali Therapeutics (DNLI), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Its Competitors CG Oncology Alvotech Catalyst Pharmaceuticals Tarsus Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Mineralys Therapeutics ImmunityBio Denali Therapeutics Disc Medicine CG Oncology (NASDAQ:CGON) and Organogenesis (NASDAQ:ORGO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Do institutionals & insiders believe in CGON or ORGO? 26.6% of CG Oncology shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 33.0% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is CGON or ORGO more profitable? Organogenesis has a net margin of -1.92% compared to CG Oncology's net margin of -15,945.17%. Organogenesis' return on equity of -0.37% beat CG Oncology's return on equity.Company Net Margins Return on Equity Return on Assets CG Oncology-15,945.17% -19.37% -18.72% Organogenesis -1.92%-0.37%-0.20% Do analysts rate CGON or ORGO? CG Oncology currently has a consensus target price of $53.91, suggesting a potential upside of 60.30%. Organogenesis has a consensus target price of $7.50, suggesting a potential upside of 54.32%. Given CG Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe CG Oncology is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92Organogenesis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has stronger earnings and valuation, CGON or ORGO? Organogenesis has higher revenue and earnings than CG Oncology. Organogenesis is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCG Oncology$551K4,653.76-$88.04M-$1.77-19.00Organogenesis$429.31M1.44$860K-$0.14-34.71 Which has more volatility and risk, CGON or ORGO? CG Oncology has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Does the media prefer CGON or ORGO? In the previous week, CG Oncology had 27 more articles in the media than Organogenesis. MarketBeat recorded 31 mentions for CG Oncology and 4 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.76 beat CG Oncology's score of 0.59 indicating that Organogenesis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 12 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Organogenesis 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryOrganogenesis beats CG Oncology on 10 of the 17 factors compared between the two stocks. Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$616.53M$2.64B$5.78B$10.04BDividend YieldN/A49.23%5.27%4.52%P/E Ratio-34.7123.7475.5726.08Price / Sales1.44501.55516.51171.66Price / Cash22.86167.9837.2059.76Price / Book2.335.2711.536.20Net Income$860K$32.95M$3.29B$270.65M7 Day Performance-2.02%1.34%0.44%2.77%1 Month Performance6.81%30.71%10.84%8.83%1 Year Performance89.84%2.03%61.62%27.49% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis3.9759 of 5 stars$4.86-0.6%$7.50+54.3%+92.5%$616.53M$429.31M-34.71950News CoveragePositive NewsCGONCG Oncology2.4382 of 5 stars$33.69+1.9%$53.91+60.0%-11.8%$2.52B$1.14M-19.0361Trending NewsAnalyst ForecastInsider TradeGap UpHigh Trading VolumeALVOAlvotech3.367 of 5 stars$8.16-2.0%$14.00+71.6%-26.9%$2.51B$491.98M35.481,032Positive NewsCPRXCatalyst Pharmaceuticals4.9022 of 5 stars$20.08-1.0%$33.20+65.3%+1.8%$2.48B$491.73M12.1780Insider TradeTARSTarsus Pharmaceuticals2.4881 of 5 stars$56.89-1.3%$66.67+17.2%+80.8%$2.43B$182.95M-24.4250Positive NewsInsider TradeIDYAIDEAYA Biosciences4.0993 of 5 stars$23.39-13.9%$45.77+95.7%-32.1%$2.38B$7M-6.1780Trending NewsAnalyst ForecastHigh Trading VolumeOCULOcular Therapeutix3.7808 of 5 stars$12.71-6.5%$17.20+35.3%+52.6%$2.37B$63.72M-9.93230Positive NewsMLYSMineralys Therapeutics2.3793 of 5 stars$35.93+3.2%$36.60+1.9%+225.2%$2.31BN/A-10.0928News CoverageAnalyst ForecastInsider TradeIBRXImmunityBio2.8257 of 5 stars$2.41+0.4%$10.75+346.1%-27.6%$2.27B$14.74M-5.02590Analyst ForecastDNLIDenali Therapeutics4.3482 of 5 stars$15.50+0.5%$33.62+116.9%-40.0%$2.26B$330.53M-5.54430News CoveragePositive NewsAnalyst ForecastIRONDisc Medicine2.6868 of 5 stars$61.91+1.9%$98.30+58.8%+16.6%$2.11BN/A-13.8530Positive NewsHigh Trading Volume Related Companies and Tools Related Companies CG Oncology Alternatives Alvotech Alternatives Catalyst Pharmaceuticals Alternatives Tarsus Pharmaceuticals Alternatives IDEAYA Biosciences Alternatives Ocular Therapeutix Alternatives Mineralys Therapeutics Alternatives ImmunityBio Alternatives Denali Therapeutics Alternatives Disc Medicine Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGO) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGO Stock Alerts